Yoon Kong Loke

Summary

Affiliation: University of Oxford
Country: UK

Publications

  1. ncbi Aspirin for the prevention of cardiovascular disease: calculating benefit and harm in the individual patient
    Yoon Kong Loke
    Department of Clinical Pharmacology, University of Oxford, Radcliffe Infirmary, Oxford OX2 6HE
    Br J Clin Pharmacol 55:282-7. 2003
  2. ncbi Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials
    S Derry
    Department of Clinical Pharmacology, University of Oxford, Radcliffe Infirmary, Oxford, OX2 6HE, United Kingdom
    BMC Med Res Methodol 1:7. 2001
  3. ncbi A comparison of three different sources of data in assessing the frequencies of adverse reactions to amiodarone
    Yoon K Loke
    Department of Clinical Pharmacology, University of Oxford, Radcliffe Infirmary, Oxford OX2 6HE, UK
    Br J Clin Pharmacol 57:616-21. 2004
  4. ncbi Does anybody read "evidence-based" articles?
    Yoon K Loke
    Department of Clinical Pharmacology, University of Oxford, Radcliffe Infirmary, Oxford OX2 6HE, United Kingdom
    BMC Med Res Methodol 3:14. 2003
  5. ncbi Air travel and venous thrombosis: how much help might aspirin be?
    Yoon K Loke
    University of Oxford, Oxford, United Kingdom
    MedGenMed 4:4. 2002
  6. ncbi Appetite suppressants and valvular heart disease - a systematic review
    Yoon K Loke
    Department of Clinical Pharmacology, University of Oxford, Radcliffe Infirmary, OX2 6HE, United Kingdom
    BMC Clin Pharmacol 2:6. 2002
  7. ncbi Reporting of adverse drug reactions in randomised controlled trials - a systematic survey
    Y K Loke
    Department of Clinical Pharmacology, University of Oxford, Radcliffe Infirmary, OX2 6HE, England
    BMC Clin Pharmacol 1:3. 2001
  8. ncbi Adverse drug reactions: keeping up to date
    Jeffrey K Aronson
    University Department of Clinical Pharmacology, Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HE, UK
    Fundam Clin Pharmacol 16:49-56. 2002
  9. ncbi Determining the reporting quality of RCTs in clinical pharmacology
    Edward Mills
    University of Oxford, Oxford, UK
    Br J Clin Pharmacol 58:61-5. 2004
  10. ncbi Assessing the benefit-harm balance at the bedside
    Yoon Kong Loke
    School of Medicine, Health Policy and Practice University of East Anglia, Norwich NR4 7TJ
    BMJ 329:7-8. 2004

Detail Information

Publications10

  1. ncbi Aspirin for the prevention of cardiovascular disease: calculating benefit and harm in the individual patient
    Yoon Kong Loke
    Department of Clinical Pharmacology, University of Oxford, Radcliffe Infirmary, Oxford OX2 6HE
    Br J Clin Pharmacol 55:282-7. 2003
    ..To estimate the absolute reduction in the risk of cardiovascular events and absolute increase in gastrointestinal haemorrhage associated with aspirin for individuals with different baseline risks...
  2. ncbi Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials
    S Derry
    Department of Clinical Pharmacology, University of Oxford, Radcliffe Infirmary, Oxford, OX2 6HE, United Kingdom
    BMC Med Res Methodol 1:7. 2001
    ..We have determined how often automated search methods, using indexing terms and/or textwords in the title or abstract, would fail to retrieve trials with adverse effects data...
  3. ncbi A comparison of three different sources of data in assessing the frequencies of adverse reactions to amiodarone
    Yoon K Loke
    Department of Clinical Pharmacology, University of Oxford, Radcliffe Infirmary, Oxford OX2 6HE, UK
    Br J Clin Pharmacol 57:616-21. 2004
    ....
  4. ncbi Does anybody read "evidence-based" articles?
    Yoon K Loke
    Department of Clinical Pharmacology, University of Oxford, Radcliffe Infirmary, Oxford OX2 6HE, United Kingdom
    BMC Med Res Methodol 3:14. 2003
    ..Editorials (average of 2537 hits per article) were viewed much more frequently than Papers, even where the editorial was written as an accompanying piece with a direct link to the paper...
  5. ncbi Air travel and venous thrombosis: how much help might aspirin be?
    Yoon K Loke
    University of Oxford, Oxford, United Kingdom
    MedGenMed 4:4. 2002
    ..If the rate of travel-related DVT is 20 per 100,000 travelers, then we will have to treat 17,000 people with aspirin to prevent 1 additional DVT...
  6. ncbi Appetite suppressants and valvular heart disease - a systematic review
    Yoon K Loke
    Department of Clinical Pharmacology, University of Oxford, Radcliffe Infirmary, OX2 6HE, United Kingdom
    BMC Clin Pharmacol 2:6. 2002
    ..Our objective was to systematically assess the risk of valvular heart disease with appetite suppressants...
  7. ncbi Reporting of adverse drug reactions in randomised controlled trials - a systematic survey
    Y K Loke
    Department of Clinical Pharmacology, University of Oxford, Radcliffe Infirmary, OX2 6HE, England
    BMC Clin Pharmacol 1:3. 2001
    ..However, some researchers have found numerous deficiencies in trial reports of adverse effects. We sought to confirm these findings by evaluating trials of drug therapy published in seven eminent medical journals in 1997...
  8. ncbi Adverse drug reactions: keeping up to date
    Jeffrey K Aronson
    University Department of Clinical Pharmacology, Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HE, UK
    Fundam Clin Pharmacol 16:49-56. 2002
    ..Systematic reviews are too few in number (only 1.25% of publications on adverse drug reactions cited in Side Effects of Drugs Annual); more are needed...
  9. ncbi Determining the reporting quality of RCTs in clinical pharmacology
    Edward Mills
    University of Oxford, Oxford, UK
    Br J Clin Pharmacol 58:61-5. 2004
    ..The Consolidated Standards for Reporting Trials (CONSORT) are recommendations for improving the quality of reports of randomized controlled trials (RCTs)...
  10. ncbi Assessing the benefit-harm balance at the bedside
    Yoon Kong Loke
    School of Medicine, Health Policy and Practice University of East Anglia, Norwich NR4 7TJ
    BMJ 329:7-8. 2004